Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
Pygl N/A
Sequence Length (AA) Molecular Weight (Da)
850 97463
Protein Name
Glycogen phosphorylase, liver form
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MAKPLTDQEK RRQISIRGIV GVENVAELKK GFNRHLHFTL VKDRNVATPR
60 70 80 90 100
DYYFALAHTV RDHLVGRWIR TQQHYYDKCP KRVYYLSLEF YMGRTLQNTM
110 120 130 140 150
INLGLQNACD EAIYQLGLDM EELEEIEEDA GLGNGGLGRL AACFLDSMAT
160 170 180 190 200
LGLAAYGYGI RYEYGIFNQK IREGWQVEEA DDWLRHGNPW EKARPEFMLP
210 220 230 240 250
VHFYGRVEHT QTGTKWVDTQ VVLALPYDTP VPGYMNNTVN TMRLWSARAP
260 270 280 290 300
NDFNLQDFNV GDYIQAVLDR NLAENISRVL YPNDNFFEGK ELRLKQEYFV
310 320 330 340 350
VAATLQDVIR RFKASKFGSK DGMGTVFDAF PDQVAIQLND THPALAIPEL
360 370 380 390 400
MRIFVDIEKL PWAKAWEITK KTFAYTNHTV LPEALERWPV ELVEKLLPRH
410 420 430 440 450
LEIIYEINQK HLDRIVALFP KDISRMRRMS LIEEEGGKRI NMAHLCIVGC
460 470 480 490 500
HAVNGVAKIH SDIVKTQVFK DFSELEPDKF QNKTNGITPR RWLLLCNPGL
510 520 530 540 550
ADLIAEKIGE DYVKDLSQLT KLHSFVSDDI FLREIAKVKQ ENKLKFSQFL
560 570 580 590 600
EKEYKVKINP SSMFDVHVKR IHEYKRQLLN CLHVITMYNR IKKDPKKFFV
610 620 630 640 650
PRTVIIGGKA APGYHMAKMI IKLITSVAEV VNNDPMVGSK LKVIFLENYR
660 670 680 690 700
VSLAEKVIPA TDLSEQISTA GTEASGTGNM KFMLNGALTI GTMDGANVEM
710 720 730 740 750
AEEAGEENLF IFGMRVDDVA ALDKKGYEAK EYYEALPELK LVIDQIDNGF
760 770 780 790 800
FSPNQPDLFK DIINMLFYHD RFKVFADYEA YVKCQEKVSQ LYMNQKAWNT
810 820 830 840 850
MVLKNIAASG KFSSDRTIKE YAKDIWNMEP SDLKISLSNE SSNGVSANGK

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for non-CPTAC-3937 Collapse assay details

Data source: Panorama

Official Gene Symbol
Pygl
Peptide Sequence
VFADYEAYVK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
774
Peptide End
783
CPTAC ID
non-CPTAC-3937
Peptide Molecular Mass
1,203.5812
Species
Mus musculus (Mouse)
Assay Type
Direct MRM
Matrix
Plasma
Submitting Laboratory
UVic-Genome BC Proteomics Centre
Submitting Lab PI
Christoph Borchers

Publication

View Details (opens in a new window)

Molecular phenotyping of laboratory mouse strains using 500 multiple reaction monitoring mass spectrometry plasma assays. Michaud SA, Sinclair NJ, Petrošová H, Palmer AL, Pistawka AJ, Zhang S, Hardie DB, Mohammed Y Eshghi A1, Richard VR, Sickmann A, Borchers CH. Commun Biol. 2018 Jun 27;1:78. doi: 10.1038/s42003-018-0087-6. eCollection 2018.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Agilent 6490/6495 QQQ
Internal Standard
synthetic peptide
Peptide Standard Purity
>80%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
1290 LC (Agilent)
Column Packing
Zorbax Eclipse Plus C18, 1.8 µm
Column Dimensions
2.1 x 150 mm
Flow Rate
400 µL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b4 (2+) 53.8 40.1 80.2 52.1 74.9 107.7 74.9 85 134.3 15 15 15
b2 (1+) 8.7 4.5 3.3 8.9 7.7 6.1 12.4 8.9 6.9 15 15 15
y9 (2+) 19.1 6.4 8.6 30.3 10.2 11 35.8 12 14 15 15 15
y7 (1+) 10.7 5.1 3.2 11.5 10.9 7.1 15.7 12 7.8 15 15 15
y8 (1+) 4.9 3.8 3.6 6.5 10.4 7.2 8.1 11.1 8 15 15 15
sum 4.2 1.9 2.6 7.3 9.1 6.5 8.4 9.3 7 15 15 15


Additional Resources and Comments